HK1207967A1 - 疫苗 - Google Patents
疫苗Info
- Publication number
- HK1207967A1 HK1207967A1 HK15108578.6A HK15108578A HK1207967A1 HK 1207967 A1 HK1207967 A1 HK 1207967A1 HK 15108578 A HK15108578 A HK 15108578A HK 1207967 A1 HK1207967 A1 HK 1207967A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261656242P | 2012-06-06 | 2012-06-06 | |
US201361768905P | 2013-02-25 | 2013-02-25 | |
PCT/EP2013/061752 WO2013182662A1 (en) | 2012-06-06 | 2013-06-06 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207967A1 true HK1207967A1 (zh) | 2016-02-19 |
Family
ID=48577074
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108547.4A HK1208150A1 (zh) | 2012-06-06 | 2015-09-01 | 疫苗 |
HK15108546.5A HK1207829A1 (zh) | 2012-06-06 | 2015-09-01 | 疫苗 |
HK15108578.6A HK1207967A1 (zh) | 2012-06-06 | 2015-09-02 | 疫苗 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108547.4A HK1208150A1 (zh) | 2012-06-06 | 2015-09-01 | 疫苗 |
HK15108546.5A HK1207829A1 (zh) | 2012-06-06 | 2015-09-01 | 疫苗 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10335482B2 (zh) |
EP (3) | EP2858667A1 (zh) |
JP (1) | JP2015520179A (zh) |
KR (1) | KR20150029678A (zh) |
CN (1) | CN104717974A (zh) |
AU (2) | AU2013273483A1 (zh) |
CA (2) | CA2875624A1 (zh) |
EA (1) | EA201492260A1 (zh) |
HK (3) | HK1208150A1 (zh) |
IL (1) | IL235890A0 (zh) |
IN (1) | IN2014KN02774A (zh) |
MX (1) | MX2014014668A (zh) |
WO (2) | WO2013182660A1 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
WO2014085489A1 (en) | 2012-11-30 | 2014-06-05 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
CN104069106A (zh) * | 2013-03-27 | 2014-10-01 | 南通瑞思医药技术有限公司 | 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用 |
WO2015086738A2 (en) * | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
CN106061476B (zh) * | 2013-12-17 | 2021-06-08 | 港大科桥有限公司 | 异黄酮在逆转录病毒感染治疗中的应用 |
WO2015110659A1 (en) * | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response |
CA2936335A1 (en) * | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Dosage regimen for hiv vaccine |
US10143737B2 (en) | 2014-01-27 | 2018-12-04 | Bionor Pharma Asa | Method for the vaccination against HIV |
EP3166633A1 (en) * | 2014-07-11 | 2017-05-17 | Bionor Immuno AS | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
MX2017000026A (es) | 2014-07-11 | 2017-05-01 | Gilead Sciences Inc | Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih). |
US9732119B2 (en) * | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) * | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) * | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) * | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
CN105878231A (zh) * | 2015-01-26 | 2016-08-24 | 复旦大学 | 黄酮类化合物在制备抗hiv潜伏的治疗药物中的用途 |
US20180169108A1 (en) * | 2015-02-20 | 2018-06-21 | The Johns Hopkins University | Drug Combinations For the Treatment of HIV |
CA2984991A1 (en) * | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
WO2017007994A1 (en) * | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
WO2017060524A1 (en) * | 2015-10-09 | 2017-04-13 | 4Sc Ag | (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections |
US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
CN108883100B (zh) | 2016-01-15 | 2022-11-25 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
US10143746B2 (en) * | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
EP4036231A1 (en) | 2016-03-09 | 2022-08-03 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US11976292B2 (en) | 2016-06-08 | 2024-05-07 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
CN106563124A (zh) * | 2016-10-19 | 2017-04-19 | 广西大学 | 硫辛酸作为疫苗佐剂的应用 |
WO2018187231A2 (en) | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
SG11202113215UA (en) | 2019-05-31 | 2021-12-30 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
CN110423723A (zh) * | 2019-07-18 | 2019-11-08 | 南方医科大学南方医院 | 一种外周血b细胞系的构建方法及其应用 |
JP2024511657A (ja) * | 2021-03-31 | 2024-03-14 | セレロン・セラピューティクス・リミテッド | ワクチンアジュバント |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
EP0230222A1 (en) | 1986-01-06 | 1987-07-29 | F. Hoffmann-La Roche Ag | Expression of HTLV-III gag-Gene |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4925784A (en) | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
GB8629116D0 (en) | 1986-12-05 | 1987-01-14 | Hoffmann La Roche | Env/gag polypeptides |
EP0356007A3 (en) | 1988-07-22 | 1991-07-03 | Medical Research Council | Antigenic determinants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
SE468168B (sv) | 1990-02-20 | 1992-11-16 | Replico Medical Ab | Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5697151A (en) | 1995-08-07 | 1997-12-16 | General Electric Company | Method for repairing partitions of a turbine diaphragm |
DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
DE69720735T9 (de) | 1996-08-12 | 2005-08-25 | Celgene Corp. | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
CN100390163C (zh) | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途 |
MXPA01003503A (es) | 1998-10-05 | 2005-01-14 | Pharmexa As | Nuevos metodos terapeuticos de vacunacion. |
NO311807B1 (no) * | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
ES2250121T3 (es) | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias. |
ATE425177T1 (de) * | 2000-07-17 | 2009-03-15 | Astellas Pharma Inc | Reduziertes fk228 und seine verwendung |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
ES2359162T3 (es) | 2005-09-01 | 2011-05-19 | Celgene Corporation | Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas. |
WO2008069349A1 (en) * | 2006-12-06 | 2008-06-12 | Sapporo Medical University | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
JP5946766B2 (ja) * | 2009-07-03 | 2016-07-06 | ビオノール イミュノ エーエスBionor Immuno As | Hivワクチン組成物における使用又は診断手段としての使用のためのhiv関連ペプチドの組合せ又は融合物 |
US20110245154A1 (en) * | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
WO2012051492A2 (en) | 2010-10-14 | 2012-04-19 | University Of Georgia Research Foundation, Inc. | Compounds and methods for inhibiting hiv latency |
AU2011335551B2 (en) | 2010-12-02 | 2016-10-06 | Bionor Immuno As | Peptide scaffold design |
CA2821995C (en) | 2011-01-06 | 2019-02-12 | Bionor Immuno As | Monomeric and multimeric peptides immunogenic against hiv |
EP2763670B1 (en) | 2011-10-03 | 2018-12-05 | Universite Libre De Bruxelles | Reactivation of hiv-1 gene expression to treat persistent hiv infection |
-
2013
- 2013-06-06 WO PCT/EP2013/061750 patent/WO2013182660A1/en active Application Filing
- 2013-06-06 CA CA2875624A patent/CA2875624A1/en not_active Abandoned
- 2013-06-06 EA EA201492260A patent/EA201492260A1/ru unknown
- 2013-06-06 CN CN201380036502.3A patent/CN104717974A/zh active Pending
- 2013-06-06 EP EP13730828.4A patent/EP2858667A1/en not_active Ceased
- 2013-06-06 IN IN2774KON2014 patent/IN2014KN02774A/en unknown
- 2013-06-06 MX MX2014014668A patent/MX2014014668A/es unknown
- 2013-06-06 EP EP13727203.5A patent/EP2858665A1/en not_active Withdrawn
- 2013-06-06 EP EP21176262.0A patent/EP3967323A3/en not_active Withdrawn
- 2013-06-06 CA CA2874936A patent/CA2874936A1/en not_active Abandoned
- 2013-06-06 WO PCT/EP2013/061752 patent/WO2013182662A1/en active Application Filing
- 2013-06-06 US US14/405,302 patent/US10335482B2/en active Active
- 2013-06-06 JP JP2015515531A patent/JP2015520179A/ja active Pending
- 2013-06-06 AU AU2013273483A patent/AU2013273483A1/en not_active Abandoned
- 2013-06-06 US US14/405,093 patent/US20150174235A1/en not_active Abandoned
- 2013-06-06 KR KR1020157000149A patent/KR20150029678A/ko not_active Application Discontinuation
- 2013-06-06 AU AU2013273481A patent/AU2013273481B2/en not_active Ceased
-
2014
- 2014-11-25 IL IL235890A patent/IL235890A0/en unknown
-
2015
- 2015-09-01 HK HK15108547.4A patent/HK1208150A1/zh unknown
- 2015-09-01 HK HK15108546.5A patent/HK1207829A1/zh unknown
- 2015-09-02 HK HK15108578.6A patent/HK1207967A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2858667A1 (en) | 2015-04-15 |
EP2858665A1 (en) | 2015-04-15 |
US10335482B2 (en) | 2019-07-02 |
IL235890A0 (en) | 2015-01-29 |
EP3967323A2 (en) | 2022-03-16 |
EP3967323A3 (en) | 2022-05-04 |
WO2013182660A1 (en) | 2013-12-12 |
CA2875624A1 (en) | 2013-12-12 |
CN104717974A (zh) | 2015-06-17 |
HK1207829A1 (zh) | 2016-02-12 |
HK1208150A1 (zh) | 2016-02-26 |
MX2014014668A (es) | 2015-03-19 |
US20150174235A1 (en) | 2015-06-25 |
AU2013273481B2 (en) | 2018-04-05 |
IN2014KN02774A (zh) | 2015-05-08 |
EA201492260A1 (ru) | 2015-08-31 |
WO2013182662A1 (en) | 2013-12-12 |
KR20150029678A (ko) | 2015-03-18 |
AU2013273483A1 (en) | 2014-12-11 |
AU2013273481A1 (en) | 2014-12-18 |
JP2015520179A (ja) | 2015-07-16 |
US20150132255A1 (en) | 2015-05-14 |
CA2874936A1 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207967A1 (zh) | 疫苗 | |
DK3327112T3 (en) | Agse-deficient stamme | |
EP2754580A4 (en) | DUMP TRUCK | |
DK2830816T3 (en) | Hidtil ukendt coatingkoncept | |
HK1212906A1 (zh) | 疫苗組合物 | |
PL2647387T3 (pl) | Kompozycja szczepionki | |
EP2935220A4 (en) | PERI-carbinol | |
EP2876161A4 (en) | VACCINE | |
GB201223386D0 (en) | Vaccine | |
IL231043A0 (en) | vaccine | |
ZA201500656B (en) | Marker vaccine | |
EP2920142A4 (en) | MÉTHANOFULLERRÈNES | |
GB201119999D0 (en) | Vaccine | |
EP2812698A4 (en) | TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR | |
EP2829281A4 (en) | LPS VACCINE | |
EP2763699A4 (en) | VACCINE | |
EP2920157A4 (en) | DI MACRO CYCLEN | |
EP2873363A4 (en) | DIOPSIMETER | |
EP2822599A4 (en) | VACCINE | |
EP2834250A4 (de) | Lithiumsilikate | |
GB201120000D0 (en) | Vaccine | |
GB201202090D0 (en) | Vaccine | |
GB201218407D0 (en) | Adjuvants | |
DK2846829T3 (en) | Vaccine combinations | |
GB201217321D0 (en) | Vaccine |